Stay updated with breaking news from Including Selective. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
SAN DIEGO, June 08, 2023 -- Travere Therapeutics, Inc. today announced that the Company and its collaborators will present nine abstracts, including the interim analysis from the ongoing Phase 3... | June 10, 2023
The DUPLEX Study did not achieve the primary efficacy eGFR slope endpoint over 108 weeks of treatment Secondary and topline exploratory endpoints trended favorably for sparsentan Treatment with... | May 1, 2023
The DUPLEX Study did not achieve the primary efficacy eGFR slope endpoint over 108 weeks of treatment Secondary and topline exploratory endpoints trended...
FILSPARI demonstrated a statistically significant, rapid, and sustained decline of proteinuria compared to the active control...
SAN DIEGO, April 01, 2023 -- Travere Therapeutics, Inc. today announced publication in The Lancet of the interim analysis of efficacy and safety data from the ongoing pivotal, Phase 3 PROTECT... | April 1, 2023